Comments on: Health 2.0 – Day 2

By: Hope Leman

Hope Leman — Wed, 12 Nov 2008 04:49:47 +0000

Hi, John. Thanks for comments. I can assure you that Private Access is not vaporware. Their partnership with the Genetic Alliance is solid and important, given the power of the Genetic Alliance in effecting change in health policy on many fronts. But your impressions about the relative thinness of the site in terms of detail are helpful.

By: WebMD on the iPhone « Chilmark Research

WebMD on the iPhone « Chilmark Research — Tue, 04 Nov 2008 16:32:32 +0000

[...] one wonder if it was the slick demo of A.D.A.M. that WebMD saw at the recent Health 2.0 conference or hearing Microsoft’s announcement at the Connected for Health Symposium that a [...]

By: John

John — Mon, 03 Nov 2008 17:29:01 +0000

Hope,
Thanks for the comment. As you are well-aware, there was quite a bit going on at Health 2.0 and one could certainly not cover everything, thus I missed PrivateAccess.

Just did a drive-by of their website, Unfortunately, do not share your enthusiasm. The website is horribly thin on the details, e.g., descriptions of products are just a brief paragraph long, lacks any privacy policy documentation and the list goes on.

That’s not to say they have nothing to offer, only to say the have nothing readily usable today and until they do, looks more like PowerPoint (Vaporware).

By: Hope Leman

Hope Leman — Sun, 02 Nov 2008 09:49:50 +0000

I very much enjoyed reading your reports on this conference. I would say, though, that there was something of great importance that was demoed in the Panel Discussion on Privacy. That was Private Access:

https://www.privateaccess.info/

As you say, some of the most interesting things at conferences are chats after sessions and I had a fascinating talk with Robert Shelton, CEO of Private Access. Anyone who follows clinical trials and laments the currently convoluted, inefficient system that burdens researchers and does little for patients should look into Private Access. It really could improve things hugely for scientists and patients and work wonders by fast-tracking trials. That is so crucial for diseases such as amyotrophic lateral sclerosis, for instance. It is a fascinating development in that it is an attempt to meet the privacy needs of patients and the needs of scientist for trial subjects. I really felt such a surge of hope after seeing that demoed and reading about Private Access since.

You are so are target about PharmaSURVEYOR–junky interface. Neat concept, poor execution.

Great write-up!

By: ICMCC Newspage » Blog Archive » Health 2.0 - Day 2

ICMCC Newspage » Blog Archive » Health 2.0 - Day 2 — Thu, 23 Oct 2008 18:32:39 +0000

[...] Overview John Moore, Chilmark Research, 23 October 2008 [...]